These patients with allergic and/or inflammatory disorders were not undergoing treatment with systemic steroids or immunosuppressants at the time of anti-PS response assessment, but 9 patients would have required oral steroids and/or immunosuppressants for conditions such as rheumatic diseases, cutaneous psoriasis, and connective tissue diseases. The gene discussed is PRB2; the disease is connective tissue disorder.